, Volume 9, Supplement 3, pp 62–66 | Cite as

French Economic Evaluations of Influenza and Influenza Vaccination

  • Emile Levy
Section 3: Economic Evaluation of Influenza Vaccination and Economic Modelling


The cost-of-illness studies of influenza performed in France for the years 1985 and 1989 have shown that the major economic consideration is the respective sizes of indirect and direct costs.

Depending on the point of view (from the perspective of National Health Insurance or the societal perspective) and the method used for measuring indirect costs, it was estimated that they could be between 1.5 and 9 times higher than direct costs.

A cost-benefit study of influenza vaccination for the employed adult population showed that vaccination is a cost-saving strategy, although this was also contingent upon the problems associated with measuring indirect benefits as well as the effectiveness rate of vaccination in real conditions.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Lévy E, Lafarge H. L’evaluation du cout de la grippe dans la France contemporaine. April 1987: 41 (unpublished report)Google Scholar
  2. 2.
    Ministere de la Solidarite de la Sante et de la Protection Sociale Enquete de Morbidite Hospitaliere 1985-87. Fichessynthetiques par pathologies, in documents statistiques du SESI no. 89, mail, 1990Google Scholar
  3. 3.
    Drummond M. Cost of illness studies. A major headache? Pharmacoeconomics 1992; 2 (1): 1–4PubMedCrossRefGoogle Scholar
  4. 4.
    Hodgson TA. Cost of illness on cost effectiveness analysis: a review of the methodology. Pharmacoeconomics 1994; 6 (6): 536–52PubMedCrossRefGoogle Scholar
  5. 5.
    Lafarge H, Levy P. Deux evaluations du cout de la grippe. 1990: 25 (unpublished report)Google Scholar
  6. 6.
    Caisse Nationale d’Assurance Maladie des Travailleurs Salaries. Statistoques mensuelles. Resultats a fin FevrierGoogle Scholar
  7. 7.
    Levy E, Levy P. La vaccination contre la grippe des personnes d’age actif (25-65 ans): une etude cout–benefice. Rev Epidemet Sante Publ 1992; 40: 285–95Google Scholar
  8. 8.
    Levy E. A cost–benefit study of influenza vaccination for 25 to 64 year old French people. In: Hannoun C, Kendal AP, Klenk HD, editors. Options for the control of influenza II. Amsterdam: Elsevier Science Publishing: 1993Google Scholar
  9. 9.
    Merlin M, Buisson Y. L’evaluation de l’efficacite de la vaccination antigrippale dans les armees au cours de l’hiver 1989-90,1990; BEH: 41Google Scholar
  10. 10.
    Les Comptes de la Nation 1989, INSEE, Paris: 1990Google Scholar
  11. 11.
    Couet C. Bilan demographique 1994,58 million d’inhabitants in INSEE Premiere no. 359; Paris, Fevrier: 1995Google Scholar

Copyright information

© Adis International Limited 1996

Authors and Affiliations

  • Emile Levy
    • 1
  1. 1.Laboratoire d’Economie et d’Gestion des Organisations de Santé (LEGOS)Paris-Dauphine UniversityFrance

Personalised recommendations